<DOC>
	<DOCNO>NCT01433250</DOCNO>
	<brief_summary>The study assess long-term safety tolerability AIN457 patient relapsing-remitting multiple sclerosis ( RRMS ) . In addition long-term pattern maintenance efficacy health relate quality life explore .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Efficacy AIN457 Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Was expose AIN457 placebo study CAIN457B2201 complete CAIN457B2201 study , include Visit 10 ( week 24 ) . 1 . Have treat : immunosuppressive medication azathioprine methotrexate within 1 month prior enrollment , lymphocyte count normal . immunoglobulin and/or monoclonal antibody ( exception AIN457 ) within 2 month prior enrollment , immunosuppressive effect likely persist enrollment ( presence B cell depletion rituximab treatment ) . 2 . Have receive total lymphoid irradiation , bone marrow transplantation , alemtuzumab , cladribine , cyclophosphamide , mitoxantrone immunosuppressive treatment longlasting ( 6 month ) permanent effect . 3 . Have receive live live attenuate vaccine ( include live vaccine varicellazoster virus measles ) within 2 month prior enrollment . 4 . A diagnosis chronic disease immune system MS , immunodeficiency syndrome . 5 . Current severe depression . 6 . Pregnant nursing ( lactate ) woman . 7 . Malignancy diagnose since enrollment core study ( except successfullytreated basal squamous cell carcinoma skin ) . 8 . A new diagnosis diabetes 9 . Positive test tuberculosis ( QuantiFeron chest Xray ) . 10 . Subjects clinically significant cardiac abnormality 11 . Unable unwilling undergo multiple venipuncture 12 . Unable undergo MRI scan due newly acquire claustrophobia metallic implant incompatible MRI . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Multiple Sclerosis ,</keyword>
	<keyword>demyelinate autoimmune disease ,</keyword>
	<keyword>interleukin-17 ,</keyword>
	<keyword>monoclonal human antibody</keyword>
</DOC>